Introduction

Immunity
Primary immune response
Vaccine : Protection from microbes recognized as foreign. The immune system is composed of organs & specialized cells that protect the body by identifying harmful substances & destroying them using anti-bodies, and other specialized substances & cells.
: Following antigenic challenge antibodies, specific helper and effector T lymphocytes including those producing cytokines and killer T cells are produced.
: Any preparation intending to produce immunity to a disease by stimulating the production of antibodies. Can prevent or ameliorate the effect of infections by many pathogens. Most common method of administration is by injections, but can be given orally or by nasal spray.
Candidate vaccine Vaccine efficacy
Vaccine preventable illness Vaccination : Any vaccine for which the development was foreseeable with the next decade.
: A population based measure of protection rather than a measure of antibody production in an individual. This is represented by the equation below: Rate of illness in unvaccinated population Rate of illness in vaccinated population Rate of illness in unvaccinated population : Is that portion of disease burden that could be prevented by immunization of entire target population with hypothetical vaccine 100% effective against the strain included in it.
: Is the administrations of antigenic materials to produced immunity to a disease. It was originally used specifically to describe the injection of small pox.
Types of Vaccine
Benefits of Immunization
Inactivated Vaccine: Live Attenuated Vaccines:
Consist of virus particles which are grown in culture and then killed using heat or formaldehyde. These particles are destroyed but capsid proteins are intact enough to be recognized and remembered by immune system, thus evoking a response. It is non-replicating, with less interference from circulating antibodies. Requires more doses and causes a mostly humoral immune response. The antibody titre diminishes with time.
Examples of inactivated vaccines include:
Viral-poliomyelitis (salk) hepatitis A, Rabies, influenza Bacteria-pertussis, typhoid, cholera, plague, anthrax Fractional subunit hepatitis B, acellular pertussis, human papilloma virus Toxoids diphtheria, tetanus Polysaccharide pneumococcal, meningococcal, salmonella typhi Conjugate polysaccharide-Hib, pneumococccal, meningococcal Recombinant hepatitis b , human papilloma virus, influenza Immune globulin homologous pooled antibody.hepatitis A, measles Homologous human hyperimmune globulin. PEP hepatitis B, rabies, tetanus, varicella Heterologous hyperimmune serum(antitoxin): antitoxin derived from injecting animals with the organism such as for botulism, diphtheria Monoclonal antibodies derived from the clone of antibody producing cells, e.g. RSV.
Palivizumab Produced by modifying a naturally occurring organism (wild) usually by repeated culturing, and retains the ability to replicate and produce immune response similar to natural infection. Circulating antibody may interfere with response. Provides long lasting immunity, and one dose usually suffices. Examples of live attenuated viruses-poliomyelitis, measles, rubella, mumps, rabies, varicella, yellow fever, rotavirus, influenza. Examples of live attenuated bacteriaBacille Calmette Guerin, typhoid.
It is a proven tool for controlling & eliminating life threatening infectious diseases (over 2million deaths per year). Avoids suffering, disability and death. One of the most cost effective health investment with proven strategies that make it : Induces in the recipient a degree of immunity similar to that achieved from the natural infection, and is able to prevent clinical disease. Produced by individual immune system and the immunity are usually long lasting.
: Is the administration of exogenously preformed antibodies, and the immunity is temporary. Commonest source is that obtained transplacentally. Others are blood and blood products, immune or hyper immune globulin & animal antitoxin.
: This is made from purified toxins produced by infective agent, attenuated to neutralize this toxic effect without reducing antigenicity e.g tetanus toxoid, diphtheria toxoid.
: Ability of vaccine to elicit a particular response at a certain dose in other to work. It is a measure of a vaccine activity in biological system.
A scientifically designed and executed investigation of the effects of a drug (or vaccine) administered to human subjects. The goal is to define the safety, clinical efficacy, and pharmacological effects (including toxicity, side effects, incompatibilities, or interactions) of the drug.
: Each study subject is randomly assigned to receive either the study treatment or a placebo.
: The subjects involved in the study do not know which study treatment they receive. If the study is double-blind, the researchers also do not know which treatment is being given to any given subject.
: Allows additional insurance against bias or placebo effect. In this kind of study, all patients are given both placebo and active doses in alternating periods of time during the study.
: The use of a placebo (fake treatment) allows the researchers to isolate the effect of the study treatment. Open-label means that both the participants and the scientists know what is given.
: Is a packaging system that can help deliver the vaccine more effectively into the correct part of the body or into the correct cell to create an immune response.
: Consists of some extra genes added into the vector. This process, known as "variolation," took a variety of forms. One form consisted of removing pus and fluid from a smallpox lesion and using a needle to place it under the skin of the person to be protected. The second involved peeling scabs from lesions, drying and grinding them to a powder, and letting an uninfected person inhale this powder.
The third method involved picking up a small amount of the scab powder with a needle and then using the needle to place the powder directly into the individual's veins. Although the effects of variolation varied, ranging from causing a mild illness in most individuals to causing death in a few, the mortality and morbidity rates due to smallpox were certainly lower in populations that used variolation than in those that did not.
Edward Jenner noticed a relationship between the equine disease known as "grease" and a bovine disease known as "cow pox. "At the same time, Jenner was interested when a milkmaid told him that she could not catch smallpox because she had had cowpox. Jenner noted that there were many people like the milkmaid -people who milked cows and who did not get smallpox even when exposed repeatedly. With this in mind, Jenner undertook a daring experiment in 1796:
It soon became clear that Jenner's experiments had paid off, and that intentional infection with cowpox protected people from much more serious infection with smallpox. As a result, within a few years thousands of people protected themselves from the deadly smallpox disease by intentionally infecting themselves with cowpox. Jenner's process came to be called "vaccination," after "vacca," the Latin word for cow, and the substance used to vaccinate was called a "vaccine."
Now, over 200 years later, we have progressed from a time when vaccination was a rare event, and Jenner's theories about vaccination were not widely accepted, to the late 1900s when vaccines are so commonplace that most children receive multiple vaccinations before they reach their first birthdays. The result of such widespread vaccination has been a marked decrease in diseases which once ravaged the world's population. Tt1 at 1 contact no protection TT2 4wks later 80% protection for 3years TT3 6mths later 95% protection for 5 years TT4 1year later or in subsequent pregnancy 99% protection for 10 years Tt5 1 year later or in subsequent pregnancy 99% protection for life
Long before the causes of disease were known and the processes of recovery were understood, the Chinese trial of exposing uninfected individuals to matter from smallpox lesions was used. 
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Global Immunization Data
Firstly the primary health care services are highly ineffective and have deteriorated due to the lack of investment in personnel, facilities and drugs, and because of poor management of the existing resources. A formerly strong primary health care system in northern Nigeria has weakened over many years. Polio outbreaks, rumors on the safety of the
There is also a problem of confidence and trust by the public in the health services resulting from the poor state of the facilities and low standards of delivery. These problems have been exacerbated by "vertical" interventions undertaken by outside agencies which undermined the capacity of the local service providers to implement sustainable programmes. At the family / community level there is a low demand for immunization due to a lack of understanding of its value.
A number of new vaccines with major potential for controlling infectious diseases have just been licensed or are at advanced stages of development. Among the illnesses targeted are rotavirus diarrhoea, pneumococcal disease, malaria and HIV which together kill more than a million children each year, most of them in developing countries. Vaccine development proceeds through discovery, process engineering, toxicology and animal studies to human Phase I, II, and III, and IV trials. The process can take more than 10 years, depending on the disease. Phase I focus is on safety, involving small groups of people(20-100) Phase II moderate-sized "target" populations (persons close to the age and other xteristics for whom the vaccine is intended) to determine both safety and the stimulation of immune response (20-300) Phase III -large target populations (30-3000)to establish whether a vaccine actually prevents a disease as intended (efficacy) , Phase IV trial is also known as post marketing surveillance trial. It involves the safety surveillance (pharmacovigilance), and ongoing technical support of a drug after it receives permission to be sold.
Development of New Vaccines
The human trials More than 10 million deaths occur globally in children age < 5, of which 24% are due to VPD. The total number of children who died from diseases preventable by vaccines currently recommended by WHO, plus diseases for which vaccines are expected soon is 2.5 million. Distribution is hepatitis B: 600 000, Hib: 363 000, pertussis: 254 000, tetanus: 163 000, others (polio, diphtheria, yellow fever): 36 000.
Estimated number of deaths in children under five from diseases preventable by vaccines (excluding measles) currently recommended by WHO is 890 000 as Hib: 363 000, pertussis: 254 000, neonatal tetanus: 128 000, tetanus (non-neonatal): 16 000, others (polio, diphtheria, yellow fever): 19 000.
Estimated number of deaths in children under five due to rotavirus and pneumococcus: 1.3 million, as pneumococcal disease: 735 000, and rotavirus: 527 000.
Immunization rates in Northern Nigeria are some of the lowest in the world. According to the 2003 National Immunization Schedule the percentage of fully immunized infants on the States to be targeted was less than 1% in Jigawa, 1.5% in Yobe, 1.6% in Zamfara and 8.3% in Katsina.As a result thousands of children are dying as victims of vaccine preventable diseases. In many parts of the north, barely 10 percent of children receive all of their routine vaccines. Coverage rates for the vaccine against tetanus among women are equally low. Why?
Deaths due to vaccine-preventable diseases (VPD)
In Nigeria can spread rapidly from the tropics to the industrialized world. Several diseases of importance to the developing world are also potential bioterrorism threats. The emergence of public-private partnerships (PPPs). PPPs are coordinated by nonprofit organizations that raise money from the public sector and use this money to leverage efforts by both the public and the private sectors to develop and produce affordable vaccines for the developing world. PPPs are involved in accelerating the development of vaccines against malaria, tuberculosis and HIV. Examples of PPP are the International AIDS Vaccine Initiative, the AERAS Global TB Vaccine Foundation, the Malaria Vaccine Initiative, and the Global Alliance for Vaccines and Immunization (GAVI) The emergence of high quality vaccine producers and capable national regulatory authorities in the developing world. In Brazil, Cuba, India and Indonesia certain manufacturers have been prequalified by the World Health Organization to supply EPI vaccines for purchase by United Nations agencies. Due to location and the available market of selling vaccines, the void of the increasing departure of the international companies is being filled. developed in1896, heat-killed, phenol-preserved, injectable whole-cell, still licensed in several countries despite its high reactogenicity.
Two new vaccines are currently licensed and widely used worldwide, a subunit (Vi PS) vaccine given via the intramuscular route, andTy21a-a live attenuated S typhi strain given orally.
: Administered as one dose (25g) via the IM/SC route. It is given to schoolaged children and protective for at least three years, with a good safety profile. It is poorly immunogenic in infants and not used in children less than 2 years of age.
: The first live oral typhoid fever vaccine, administered as enteric-coated capsules to be swallowed every other day for one week. The vaccine is protective for at least 5-7 years.
Rotavirus diarrhoea is a leading cause of severe diarrhoeal disease and dehydration in infants and under-5 yrs children globally. Three oral RV vaccines are currently licensed. Increasing divergence between vaccine products used in the industrialized versus developing worlds. This divergence include newer generation vaccines, several vaccines and vaccine formulations that had formerly been used jointly in industrialized and developing country populations ceased to be recommended in industrialized countries. Little incentive for the vaccine industry in the industrialized world to develop new vaccines against diseases that were largely limited to the developing world, as industrialized world markets are more lucrative. The increasing stringency of regulations imposed by national vaccine licensing authorities usually result in an increase in the costs of clinical development pathways for licensure of vaccine candidates to hundreds of millions of dollars. New generation vaccines would have to cost dollars per dose in order for industry to recover an adequate return on its investmentin contrast to the pennies per dose cost of the traditional EPI vaccine. It had become increasingly common to find that vaccines performed less well in developing country populations than in populations residing in the industrialized world. Trials of vaccines in developing countries were needed before their introduction in these settings, and trials in developing countries -not a priority for large producers in the industrialized world. If they were undertaken, they were typically deferred for years after vaccine licensure in industrialized To overcome the disincentives to industry of creating new vaccines for the developing world, Governments in the industrialized world have traditionally used 'push mechanisms. Push mechanisms -aim is to lower the risks and costs to industry of research and development, and includes; providing grants for product development, supporting the costs of clinical trials, strengthening of field sites in developing countries, providing research and development tax credits and expediting the regulatory and licensing process. Increased funding-major contributors are foundations. This is due to the increasing recognition that infectious diseases are major threats to global security, and infectious diseases
Opportunities for vaccine introduction
Pneumococcal conjugate vaccines (PCV): S. pneumoniae Haemophilus influenzae type b (Hib) Vaccines
Haemophilus influenzae
Hib conjugate vaccines Malaria Vaccine
The first PCV, Prevnar (Wyeth), is recommended for routine use in children aged less than two years. It is administered in a 3 doses schedule, and when possible in combination with usual routine vaccination, followed by a booster dose at 15-18 months. Alternatively, the vaccine can be administered in a two-dose immunization schedule at 3 and 5 months of age, followed by a booster immunization at 11-12 months of age. It contains poly-or oligo-saccharides from seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F), each conjugated to genetically detoxified diphtheria toxin CRM 197. Currently there are at least the PCV-10 and PCV-13 being used mainly in the private sector and in the high risk populations in Nigeria.
Infections by type b are responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in children aged less than 5 years. It is estimated to cause at least 3 million cases of serious disease every year, and approximately 386 000 deaths. The vaccines are formulated either as single antigens or as part of combination vaccines. Hib vaccines are safe and efficacious even when administered in early infancy. Liquid Hib vaccines are used directly from the vial, whereas freeze-dried vaccines must be reconstituted before administration, either with diluent or with another vaccine that has been specifically identified and indicated for this purpose by the manufacturer, such as DTP.
Approximately 350500 million cases of malaria occur annually, killing between one and three million people, the majority of whom are young children in sub-Saharan Africa. Ninety percent of malariarelated deaths occur in sub-SaharanAfrica. A good antibody response is achieved following a single IM injection in 60-80% of healthy adults and normal children over two years of age. PPV23 is unable to elicit immune memory, so that a second dose of vaccine does not boost antibody levels. Also, PPV23 does not provide protection against mucosal infection, and is thus unable to reduce nasopharyngeal carriage of pneumococci. It is poorly immunogenic in less than 2 years old children and is thus not used in infants and young children. 
Streptococcus pneumoniae Vaccine
Steptococcus pneumoniae: 
23-valent polysaccharide vaccine (PPV23):
· · · · · · · · · · · ·
Pay for its use (GAVI)
st
Conclusion Acknowledgement
Malaria vaccines are in the developmental phase, and there are different strategies been developed based on the life cycle of the Plasmodium spp.
Pre-erythrocytic vaccine strategies prevent infection and/or reduce incidence and severity of disease. Aim is to generate an antibody response that will neutralize sporozoites and prevent them from invading the hepatocyte, and/or to elicit a cellmediated immune response that will inhibit intrahepatic parasites.
Asexual blood-stage (erythrocytic) vaccine strategies reduce disease incidence and severity. Aim is to elicit antibodies that will inactivate merozoites and/or target malarial antigens expressed on the RBC surface, thus inducing antibody-dependent cellular cytotoxicity and complement lysis; they also are intended to elicit T-cell responses that will inhibit the development of the parasite in RBCs : Sexual blood stage (transmission blocking) malaria vaccines are targeting gametocytes, gametes and/or zygotes. It aims to prevent man to mosquito transmission.
The RTS, S vaccine is the first malaria vaccine candidate to demonstrate that young children and infants exposed to intense transmission can be protected from infection and malaria disease. Current malaria prevention programs and national immunization programs need to be strengthened in order to be prepared for the introduction of malaria vaccines when approved by regulatory authorities and recommended as an additional anti-malaria tool.
Lack of disease burden data Weak health systems and its attendant poor logistics such as cold chain Poor transportation and storage systems Inadequate and poorly motivated health care worker Lack of political will Barriers to use of "new" vaccines Poor health financing Weak community participation Lack of sustainable partnerships
Generation of local burden of disease data (disease surveillance systems, regional sentinel sites) which can be used to create awareness and sensitized the population to support the vaccine.
Plasmodium falciparum Advocate its use
Barriers to Use of Existing Childhood Vaccines
Improving Vaccine Use in Developing Countries
